#AS­CO22: Fol­low­ing back-to-back TIG­IT bombs, Roche of­fers in­sight in­to first PhI­II tri­al fail

Roche’s Genen­tech suf­fered two con­sec­u­tive Phase III fails for tiragolum­ab, the ear­li­est in a se­ries of an­ti-TIG­IT drugs from Big Phar­mas hop­ing to ush­er in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER